Literature DB >> 30665484

Necrolytic Migratory Erythema: Complete Healing after Surgical Removal of Pancreatic Carcinoma.

Marija V'lckova-Laskoska1, Margareta Balabanova-Stefanova, Irina Arsovska-Bezhoska, Nina Caca-Biljanovska, Dimitri Laskoski.   

Abstract

Necrolytic migratory erythema is considered an obligatory cutaneous paraneoplastic sign associated with glucagonoma. Glucagonoma syndrome is defined by the presence of an alpha-cell secreting tumor of the pancreas, elevated levels of glucagon, and a characteristic rash called necrolytic migratory erythema. Although necrolytic migratory erythema is a specific finding in glucagonoma syndrome, it may occur in other settings, unassociated with an alpha-cell pancreatic tumor (pseudoglucagonoma syndrome). The rarity of glucagonoma imposes a challenge, with most patients being diagnosed after a long period of treatment for their skin rash. The main prognostic sign of glucagonoma are the subsequent metastases that come late in the course of the disease. Herein, we present a 55-year-old female patient with a 5-year history of unrecognized cutaneous and systemic manifestations of glucagonoma syndrome. Based on the investigations, the diagnosis of glucagonoma syndrome without metastases was established. After surgical removal of pancreatic carcinoma/glucagonoma, complete healing and a long disease-free period was achieved. Appropriate awareness of the characteristics of necrolytic migratory erythema in physicians/dermatologists often leads to an early diagnosis of glucagonoma syndrome and enhances the chances of a favorable outcome.

Entities:  

Mesh:

Year:  2018        PMID: 30665484

Source DB:  PubMed          Journal:  Acta Dermatovenerol Croat        ISSN: 1330-027X            Impact factor:   1.256


  1 in total

1.  Case of delayed diagnosis of necrolytic migratory erythema.

Authors:  Wissal Abdelli; Fatima Alaoui; Asmahen Souissi; Wiem Sassi; Ines Chelly; Slim Haouet; Mourad Mokni
Journal:  Clin Case Rep       Date:  2021-12-11
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.